Verition Fund Management’s Humacyte HUMA Stock Holding History

Verition Fund Management’s Portfolio HUMA Stock Details HUMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$19K	Buy	+24,300	New	+$22.5K	﹤0.01%	2018

Other funds holding HUMA

Antipodes Partners Royal Exchange, Australia $5.46B AUM 26.64% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Verition Fund Management's HUMA Position: Q2 2025 in Review

Verition Fund Management sold out of Humacyte (HUMA) in Q2 2025, closing a stake of 60,505 shares — an estimated $103K sold.

Verition Fund Management first reported a position in HUMA in Q1 2021 and held it in 6 quarters. The position peaked at $491K in Q3 2024. 156 funds tracked by Wall St. Rank hold HUMA as of Q2 2025.

Verition Fund Management reported no remaining Humacyte position as of Q2 2025 after selling out during the quarter.
Verition Fund Management sold 60,505 Humacyte shares in Q2 2025, an estimated $103K.
Verition Fund Management first reported a position in Humacyte in Q1 2021 and held it in 6 quarters.
Verition Fund Management's Humacyte position peaked at $491K in Q3 2024.
156 funds tracked by Wall St. Rank held Humacyte as of Q2 2025.

Based on Verition Fund Management's 13F filing for Q2 2025, filed 14 Aug 2025.